Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 14, 2026
Yubo International Biotech Limited (YBGJ) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $247,949. As of Jun 30, 2026 it held $11,989 in cash and investments and $15,655 in total debt.
Revenue
$0
Net income
$-247,949
-7.6% vs year-ago quarter
Operating cash flow
$-84,104
-499.5% vs year-ago quarter
Free cash flow
$-207,157
+48.0% vs year-ago quarter
EPS
$0.00
Dividend per share
None
Shares outstanding
170.42M
+42.2% vs year-ago quarter
Net cash
$-3,666
Q2 FY2026
Operating margin
-9096.9%
TTM
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- YBGJ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Beijing, China
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 895464
- Former names
- MAGNA LAB INC (until Dec 4, 2020)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $12,353 | $0 | $0 |
| Operating income | -$238,860 | -$289,274 | -$285,468 | -$310,134 | -$249,699 |
| Net income | -$247,949 | -$272,608 | -$176,960 | -$310,152 | -$230,333 |
| Diluted EPS | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | -$84,104 | -$207,157 | -$128,752 | -$307,979 | -$14,028 |
| Free cash flow | — | -$207,157 | — | — | — |
| Total assets | $672,272 | $709,872 | $847,094 | $953,211 | $1.1M |
| Total liabilities | $3.3M | $3.0M | $2.8M | $2.6M | $5.0M |
| Stockholders' equity | -$2.6M | -$2.3M | -$2.0M | -$1.7M | -$4.0M |
| Cash and investments | $11,989 | $10,382 | $8,062 | $10,926 | $10,416 |
| Total debt | $15,655 | $39,215 | $78,782 | $138,604 | $184,893 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jun 12, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Auditor change
|
Jan 16, 2026 | Jan 13, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 284 Yubo International Biotech Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.